IL17A and Granuloma: The granuloma score in the PDE-challenged mice was significantly increased on day 10 compared with the control mice (control mice: 0.02 ± 0.02, PDE-challenged mice: 1.18 ± 0.17; P < 0.001; Fig 3B), and the score in the PDE-challenged mice that were administered the anti-IL-17A antibody was significantly decreased compared with the PDE-challenged mice (PDE-challenged mice administered the anti-IL-17A antibody: 0.50 ± 0.16; P = 0.021; Fig 3B).